243 related articles for article (PubMed ID: 25116964)
1. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
2. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
[No Abstract] [Full Text] [Related]
3. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
Francini E; Bianco V
Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
[No Abstract] [Full Text] [Related]
4. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
[No Abstract] [Full Text] [Related]
5. Grade III hand-foot skin reaction induced by sorafenib.
Chiriac A; Coros MF; Podoleanu C; Stolnicu S
An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
[No Abstract] [Full Text] [Related]
6. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
[TBL] [Abstract][Full Text] [Related]
7. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
Xu L; Wang B; Ding W
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
[No Abstract] [Full Text] [Related]
8. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
[No Abstract] [Full Text] [Related]
9. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
10. Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib.
Madabhavi I; Patel A; Anand A; Choudhary M; Revannasiddaiah S
J Cancer Res Ther; 2015; 11(4):1029. PubMed ID: 26881607
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib plus cisplatin for hepatocellular carcinoma.
Brower V
Lancet Oncol; 2016 Oct; 17(10):e424. PubMed ID: 27617663
[No Abstract] [Full Text] [Related]
12. Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
Coppola R; Zanframundo S; Rinati MV; Carbotti M; Graziano A; Galati G; De Florio L; Panasiti V
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1028-9. PubMed ID: 24628665
[No Abstract] [Full Text] [Related]
13. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
14. Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
Chou JW; Cheng KS; Huang CW
Intern Med; 2016; 55(6):623-7. PubMed ID: 26984079
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
Di Costanzo GG; de Stefano G; Tortora R; Farella N; Addario L; Lampasi F; Lanza AG; Cordone G; Imparato M; Caporaso N
Future Oncol; 2015; 11(6):943-51. PubMed ID: 25760975
[TBL] [Abstract][Full Text] [Related]
16. Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
Takahashi Y; Fukunishi S; Nishikawa T; Nouda S; Sasaki Y; Sanomura M; Umegaki E; Higuchi K
Endoscopy; 2013; 45 Suppl 2 UCTN():E179-80. PubMed ID: 23801291
[No Abstract] [Full Text] [Related]
17. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
[No Abstract] [Full Text] [Related]
18. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Ganten MK; Schuessler M; Bruckner T; Ganten TM; Koschny R
Oncology; 2015; 89(2):88-94. PubMed ID: 25871578
[TBL] [Abstract][Full Text] [Related]
20. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
